This book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers.

Explores potentials of PROTAC-based therapies in combating cancer Covers all aspects related to PROTACs, including history, mechanisms, design, and clinical development Defines the concept of a fundamental approach toward traditional drug development

Autorentext

Dr. Mukesh Nandave is currently serving as the Associate Dean (Research & Consultancy) and Associate Professor, as well as the Head of the Department of Pharmacology and Pharmaceutical Biotechnology at Delhi Pharmaceutical Sciences and Research University, under the Government of NCT of Delhi, India. Dr. Nandave completed his Ph.D. in Pharmacology from AIIMS in Delhi and pursued his post-doctoral training at the Ohio State University Medical Center in Columbus, USA. Dr. Nandave has primarily focused his research on investigating the role of nutraceuticals, herbomineral formulations, and phytoconstituents in areas such as myocardial ischemia & reperfusion injury, diabetes, obesity, cancer, and pain management. He has published over 120 papers in national and international peer-reviewed journals, and received several prestigious awards, including the distinguished leadership award of the International Academy of Cardiovascular Sciences, and holds various professional memberships.

Dr. Priti Jain is an Assistant Professor at the Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, New Delhi. She has more than 15 years of experience in industrial and academic research. Her area of research is mainly focused on in silico design and the discovery of low molecular weight heterocycles as anti-Alzheimer's agents, anti-cancer agents, and anti-HIV agents. Dr Jain is involved in research on analytical method development and validation of API and dosage forms. She has published more than 40 research articles in peer-reviewed international journals and authored or co-authored numerous books and book chapters. Jain serves as an editor for various journals and a reviewer of many reputed journals. She is also a Bentham Brand Ambassador since 2018 and has been conferred with various awards. She is a member of many international scientific societies and organizations.

Inhalt

1. Understanding the Ubiquitin Proteasome System - History and Revolution.- 2. PROTACs: Principles and Mechanisms.- 3. Structural Considerations and Chemistry of PROTAC.- 4. Advantages and Disadvantages of PROTACs.- 5. Novel Technologies in PROTAC Design.- 6. Future of trends in the design and development of PROTAC.- 7. Global Regulatory Requirements Applicable for PROTACs.- 8. Tissue-Specific Targeting Strategies with PROTAC Technology.- 9. Clinical Development OF PROTACs.- 10. Toxicological Aspects of PROTACs.- 11. PROTACs in the management of Prostate Cancer.- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer.- 13. Role of PROTACs in Hematological Malignancies.- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells.- 15. PROTACs in Treatment of Glioma.- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges.- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.